On April 17, 2026 Ultima Genomics, a developer of an innovative, ultra-high throughput sequencing architecture reported key milestones for its ppmSeq technology with a growing body of evidence from data presented across six abstracts, including an oral session and a plenary session at the 2026 AACR (Free AACR Whitepaper) Annual Meeting in San Diego, taking place April 17–22, 2026. Highlighting the program will be initial TRACERx MRD data showcasing the performance of ppmSeq relative to ultrasensitive bespoke panels. Data from collaborators, including LabCorp and DELFI Diagnostics, will also be presented at the conference. Collectively, these add to the growing body of evidence establishing ppmSeq as a new standard for ultrasensitive MRD, providing low single-digit parts-per-million sensitivity, with a simple, scalable, and distributable whole genome workflow that can be deployed globally.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We built ppmSeq to find tumor-derived molecules in a sea of normal DNA, without the need to produce a customized assay for every patient," said Gilad Almogy, Founder and CEO of Ultima Genomics. "The data presented at AACR (Free AACR Whitepaper) this week demonstrate these capabilities and point toward a future where whole-genome MRD is the standard of care for patients globally."

Ultima showcases low single-digit parts-per-million accuracy across tumor types to be shown at AACR (Free AACR Whitepaper) 2026

Today, Ultima is showcasing low single-digit parts-per-million levels of accuracy across tumor types, which include samples from the TRACERx (TRAcking Cancer Evolution through therapy (Rx)) cancer program, one of the largest tumor evolution studies funded by Cancer Research UK to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients.

Led by Professor Charles Swanton (UCL / Cancer Research UK / The Francis Crick Institute), an early validation pilot of ppmSeq across 50 plasma samples — using tumor-specific variants identified from prior whole genome sequencing — achieved high analytical sensitivity for ctDNA detection at low single-digit parts-per-million, without the complexity of bespoke panel approaches. Results will be presented at a plenary and a late-breaking oral session during the conference.

"TRACERx has always followed the science of cancer evolution wherever it leads," said Charles Swanton, Deputy Clinical Director at The Francis Crick Institute. "Improving the sensitivity of ctDNA detection is central to the wider ambition for MRD monitoring, and expanding studies across a broader patient population will give us the statistical power and clinical context to determine how whole genome MRD monitoring can be deployed at NHS scale and beyond."

"The ability to perform personalized, tumor-guided ctDNA detection at parts-per-million sensitivity — without bespoke panel design and production — fundamentally changes what is achievable in lung cancer MRD monitoring," said Dan A. Landau, MD, PhD, a core member at the New York Genome Center, and Professor of Medicine & Professor of Physiology and Biophysics at Weill Cornell Medicine.

Additional work will assess prognostic performance at scale, and with the created dataset, explore tumor-agnostic MRD approaches that require no prior knowledge of a patient’s tumor mutational profile. Follow-up data will be presented later in 2026.

Other collaborators, including Labcorp and DELFI Diagnostics, to present data addressing clinical implementation of ppmSeq and enablement of new applications at AACR (Free AACR Whitepaper) 2026

In addition to the TRACERx data, important collaborators will showcase the clinical implementation and real-world deployment of ppmSeq whole genome sequencing, including:

Labcorp: Analytical performance of an ultrasensitive whole genome sequencing assay for molecular residual disease detection – Poster No. 5307/2

Labcorp will present data from an independent analytical study of an assay developed in coordination with ppmSeq technology, including the performance across multiple solid tumor types in pre-surgical, treatment-naive plasma samples. This analysis of 120 non-cancerous donor samples showed specificity exceeding 99.9%, underscoring the ability of ppmSeq whole genome sequencing to accurately differentiate between cancerous and non-cancerous samples, minimizing false positives. Additional analysis across three commercially available cancer cell lines spanning 13 concentration levels from 0.5 to 500 parts per million showed a 95% limit of detection below 3 ppm, demonstrating the assay’s capacity to detect ultra-low levels of circulating tumor DNA (ctDNA). Collectively, these results represent a significant milestone in the transition from research-grade performance to clinical-grade reliability.

"The whole genome approach enabled by ppmSeq changes the operational efficiency for tumor-informed MRD testing in a reference laboratory setting," said Taylor Jensen, Ph.D., Vice President and Head of Oncology Science at Labcorp. "Eliminating the need for individualized design and physical production of a panel while maintaining low single-digit parts-per-million analytical sensitivity is the kind of advancement that makes broad clinical deployment feasible, and the analytical data we are presenting at AACR (Free AACR Whitepaper) support a compelling case for WGS-based MRD as a scalable solution."

DELFI: Enhanced cfDNA fragmentation-based treatment monitoring on the Ultima Genomics platform – Abstract No. 3863/24

This study examined the performance of DELFI-TF, a cfDNA fragmentation-based tool for monitoring cancer treatment response, across Ultima vs Illumina platforms. Fragmentation profiles were consistent across platforms, and Ultima-based DELFI-TF values strongly tracked tumor burden and longitudinal treatment response. Notably, combining DELFI-TF with Ultima’s ppmSeq enabled distinction of tumor- from normal-derived DNA fragments, opening a path toward improved ctDNA detection sensitivity.

Labcorp: Utility of TAPS+: a positive-readout methylation sequencing approach for high-fidelity epigenetic profiling – Poster No. 3213/23

This study evaluated the TAPS+ workflow from Watchmaker Genomics on a 24-sample cohort of invasive breast carcinoma patients and healthy donors. TAPS+ demonstrated higher library yields, shorter turnaround times, and enabled the identification of more potentially relevant differentially methylated regions, in addition to a higher rate of DNA methylation observed in fully methylated control samples (88.8% vs. 76.8%). Importantly, TAPS+ libraries sequenced on the Ultima Genomics UG 100 platform showed equivalent methylation patterns, conversion efficiency, and transcription sites (TSS) profiles to those generated on an alternative sequencing platform, validating cross-platform reproducibility. Together, these results position TAPS+ with Ultima WGS as a robust, platform-agnostic epigenetic profiling method suitable for clinical assay development and early cancer detection.

Ultima announces inaugural global MRD Symposium focused on the current and future state of minimal residual disease detection technologies and utility in clinical practice

Prior to AACR (Free AACR Whitepaper), Ultima Genomics will co-host its inaugural global MRD symposium alongside Dan Landau and Charles Swanton. This exclusive event will bring together leaders in oncology research to discuss clinical adoption of MRD globally, and novel sequencing approaches that provide ultra-sensitive detection, and will feature a short series of selected presentations from key experts in the pharmaceutical, translational, and research fields.

Registration and details are available at: www.ultimagenomics.com/mrd-symposium

Summary of selected presentations at AACR (Free AACR Whitepaper):

Session

Presenters

Location/Time

Presentation Title

Discovery Science Plenary

Dan Landau

Weill Cornell Medicine

PLENARY

Sat. April 18

The Next Frontier in Minimal Residual Disease: Solid Tumors

Late-Breaking Poster Session: Clinical Research (LBPO.CL02)

Jonathan Wan
Francis Crick Institute

Section 52 LB116/3

Mon. April 20

Error-corrected plasma whole-genome sequencing for personalised and tumour-agnostic minimal residual disease detection in NSCLC

Poster – Liquid Biopsies: Circulating Nucleic Acids 4 (PO.CL01.10)

Andrew Georgiadis Labcorp

Section 45 5307/2

Tues. April 21

Analytical performance of an ultrasensitive whole genome sequencing assay for molecular residual disease detection

Mini Symposium – AACR (Free AACR Whitepaper) Project GENIE Use Cases (MS.MD01.01)

Elizabeth E. Martin
Broad Institute of MIT and Harvard

Room 14 Mezzanine Level Mon. April 20

Leveraging Ultima Genomics ppmSeq WGS-cfDNA to accurately detect clonal evolution over sequential blood biopsies

Poster – Liquid Biopsies: Circulating Nucleic Acids 3 (PO.CL01.09)

Laurel K. Millberg
DELFI Diagnostics

Section 45 3863/24

Mon. April 20

Enhanced cfDNA fragmentation-based treatment monitoring on the Ultima Genomics platform

Poster – Epigenetic Changes as Molecular Markers of Cancer (PO.MCB06.03)

Kimberly A. Holden Labcorp

Section 20 3213/23

Mon. April 20

Utility of TAPS+: a positive-readout methylation sequencing approach for high-fidelity epigenetic profiling

Poster – Network Biology and Precision Medicine (PO.BCS01.14)

Orly Alter

University of Utah and Prism AI Therapeutics, Inc

Section 3 6884/28

Wed. April 22

Quantum mechanics-based multi-tensor AI/ML correctly predicts glioblastoma patients’ overall survival, gene targets, and treatment response from whole genomes

(Press release, Ultima Genomics, APR 17, 2026, View Source [SID1234664487])

On April 17, 2026 SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for early molecular residual disease (MRD) detection, reported that the company and its collaborators will present data from two abstracts at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 17–22 in San Diego, California. These abstracts showcase the ultrasensitive structural variant (SV)-based detection of circulating tumor DNA (ctDNA) in metastatic breast cancer (mBC) and high-grade serous ovarian cancer (HGSOC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SV-based ctDNA Monitoring in Metastatic Breast Cancer (mBC)

In collaboration with Drs. David Cescon and Mitchell Elliott at University Health Network (UHN) Canada, a retrospective analysis was conducted for patients with mBC (all subtypes) undergoing standard systemic therapy, utilizing the Pathlight SV-based MRD test. SAGA was able to successfully generate fingerprints in 66 patients using standard tissue-based Pathlight. Using ultradeep cfDNA-based whole-genome sequencing, SV-based tissue-free fingerprints were generated to rescue additional patients for which tissue was unavailable, enabling these patients to benefit from informed MRD testing.

The study’s SV-based approach achieved a high 77% detection rate (294/380) for ctDNA, with nearly a third of those cases identified in the ultrasensitive range. Additionally, Pathlight proved to be a powerful predictor of patient outcomes: where ctDNA was undetectable, patients showed exceptional responses to therapy, including prolonged disease stability and complete clinical response. Furthermore, Pathlight successfully tracked treatment responses across multiple lines of therapy, with rising ctDNA levels preceding radiologic signs of disease progression.

"Metastatic breast cancer remains a challenge to manage clinically, and the use of an accurate complementary biomarker may help improve the care for our patients," said Mitchell Elliott, MD, FRCPC. "By leveraging structural variants – highly conserved features of the tumor genome – we enable ultrasensitive ctDNA detection in the metastatic setting which closely aligns with standard of care radiographic assessment. This approach supports the potential for more reliable treatment monitoring and unlocks new opportunities for clinical utility in this setting."

Improved Prognostic Assessment in Ovarian Cancer

In collaboration with the Medical University of Vienna and LMU Munich, a retrospective analysis was performed on plasma samples collected prospectively from 84 patients with advanced high-grade serous ovarian cancer (HGSOC). High baseline detection was observed (94%), with MRD remaining in 85% of cases postoperatively. Within the subgroup of patients with pathological complete tumor resection, ctDNA clearance at the first cycle of chemotherapy (C1) (20%) and the sixth cycle (C6) (70%) was associated with significantly lower recurrence risk compared to those with persistent ctDNA. Most notably, ctDNA persistence at C6 was identified as a powerful independent prognostic marker, where ctDNA-positive patients faced a median time to clinical recurrence of just 10.7 months compared to 21.3 months for those who cleared ctDNA. While CA-125 levels failed to significantly predict recurrence at key treatment milestones, ctDNA dynamics offered precise risk stratification even after optimal primary surgery, providing a vital clinical window for personalized maintenance strategies and risk-adjusted treatment interventions.

"The consistent performance of SV-based MRD monitoring by Pathlight across these diverse, late-stage cancers underscores its broad clinical applicability," added Wendy Levin, MD, MS, Chief Clinical Officer of Saga Diagnostics. "This isn’t just about better data-it’s about the potential for clinical utility. By accurately informing on treatment monitoring where traditional tools fail, we are unlocking the ability to tailor therapies in real-time, ultimately improving outcomes through more informed, individualized patient management."

Key SAGA Diagnostics Presentations During AACR (Free AACR Whitepaper) 2026:

Abstract Title

Presentation Details

Tumor-informed circulating tumor DNA identifies high-grade serous ovarian cancer patients at highest risk for recurrence despite optimal first-line treatment with primary macroscopic complete resection

Poster Presentation
Location: Section 42
Date: April 19, 2026
Time: 2:00-5:00 PM
Speaker: Magdalena Postl, MD

Serial ctDNA monitoring in metastatic breast cancer using an ultrasensitive tumor-informed structural variant-based assay

Poster Presentation: #3864
Location: Section 45
Date: April 20, 2026
Time: 2:00-5:00 PM
Speaker: Mitchell Elliott, MD, FRCPC

The full abstracts for SAGA Diagnostics at AACR (Free AACR Whitepaper) 2026 can be found here.

(Press release, SAGA Diagnostics, APR 17, 2026, View Source [SID1234664503])

On April 17, 2026 Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, reported new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib in the ongoing FIT-001 clinical trial (NCT06026410) of darlifarnib (KO-2806) in combination with cabozantinib. Results were presented at the 2026 International Kidney Cancer Symposium (IKCS): Europe in Paris, France.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The analysis specifically evaluated patients with ccRCC who had previously received cabozantinib, a population that typically derives limited benefit from subsequent therapy. In this setting, the combination of darlifarnib and cabozantinib demonstrated robust antitumor activity along with a manageable safety profile as demonstrated in all RCC patients across multiple dose levels, including full dose cabozantinib. These findings are consistent with clinical and preclinical data presented at the 2025 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) and in earlier data disclosures supporting the potential of darlifarnib to enhance the activity of VEGFR-targeted therapies and to address mechanisms of resistance.

Clinical Activity in Cabozantinib-Pretreated Patients (N=16):

Objective response rate (ORR) was 44%, with a disease control rate (DCR) of 94% across all doses tested in this population

Tumor shrinkage observed in 75% of patients, with reductions ranging from 32% to 47% among responders

Antitumor activity observed in a heavily pre-treated, cabozantinib-exposed population, including patients whose best response to prior cabozantinib was stable disease

Responses observed in patients previously treated with cabozantinib in the immediate prior line as well as those who had received other TKIs in addition to cabozantinib

Treatment durations ranged from 8 to 56 weeks, with six patients remaining on therapy at the time of data cutoff

These findings are notable given that patients who progress on cabozantinib are generally considered unlikely to respond to subsequent cabozantinib therapy.

"Patients with advanced ccRCC whose disease progresses on cabozantinib have limited treatment options," said Adanma Ayanambakkam, M.D., M.S., Assistant Professor of Hematology Oncology Director of Genitourinary Medical Oncology Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center. "The tumor shrinkage and high disease control rate observed with darlifarnib in combination with cabozantinib suggest this approach may offer meaningful clinical benefit in a refractory setting or in patients with disease progression after therapy."

The FIT-001 study is evaluating darlifarnib in patients with RCC at once-daily doses of 3 mg, 5 mg or 8 mg alternating 7 days on and off in combination with cabozantinib at once-daily doses of 60 mg or 40 mg. All patients must have received prior immunotherapy. The study has advanced into Phase 1b dose expansion to assess an optimal biologically active dose for the combination.

"These data highlight the potential of darlifarnib to overcome resistance to prior cabozantinib and enhance the activity of VEGF TKIs in patients with advanced RCC," said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. "We are highly encouraged by these results and are committed to advancing this combination to evaluate further its potential to deliver meaningful benefit for RCC patients."

2026 IKCS: Europe Presentation
The presentation from 2026 IKCS: Europe is available on Kura’s website at www.kuraoncology.com under the Posters and Presentations tab in the Farnesyl Transferase Inhibition section.

Virtual Investor Event
Kura will host a webcast and conference call today, April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST featuring management and Adanma Ayanambakkam, M.D., M.S., Assistant Professor of Hematology Oncology and Director of Genitourinary Medical Oncology Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.

(Press release, Kura Oncology, APR 17, 2026, View Source [SID1234664472])

On April 17, 2026 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, reported that it has released present results from three novel programs in poster presentations at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR 2026). The presentations will feature ATG-125 (B7-H3 x PD-L1 bispecific antibody-drug conjugate [ADC]), an IO + ADC dual-function molecule being developed for the treatment of solid tumors, as well as two investigational T cell engagers (TCEs) developed using the company’s proprietary AnTenGager TCE platform, including ATG-106 (CDH6 x CD3 TCE) for ovarian and kidney cancers, and ATG-112 (ALPPL2 x CD3 TCE) for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the Poster Presentation:
ATG-125 (B7-H3 x PD-L1 bispecific ADC)
Title: ATG-125, a novel B7H3 x PD-L1 bispecific antibody-drug conjugate, demonstrates potent antitumor efficacy by dual targeting of immune evasion and direct tumor killing
Abstract Number: 5599
Session Category: Immunology
Session Title: T Cell Engagers 2 / Antibody-Drug Conjugates 1
Date: April 21, 2026
Time: 02:00 PM – 05:00 PM (Pacific Time)
05:00 AM, April 22, 2026 – 08:00 AM, April 22, 2026 (Beijing Time)
Location: Poster Section 8

Introduction: B7-H3 and PD-L1 are immune checkpoint molecules broadly overexpressed across multiple solid tumors and are associated with immune evasion and poor prognosis. Although PD-1/PD-L1-directed therapies have demonstrated clinical benefit, treatment resistance remains a significant challenge. B7-H3 is also emerging as a promising ADC target due to its broad tumor expression and rapid internalization. ATG-125 is a novel B7-H3 x PD-L1 bispecific ADC designed to combine direct tumor killing with immune activation by co-targeting two complementary tumor-associated pathways in a single molecule.
Results: ATG-125 bound to both B7-H3 and PD-L1 with high specificity and nanomolar affinity and demonstrated robust antigen-dependent internalization in dual-positive tumor cells, enabling efficient intracellular payload release. The molecule induced tumor cell apoptosis, while its parental naked antibody blocked PD-1/PD-L1 interaction and elicited IL-2 and IFN-γ production in mixed lymphocyte reaction assays. ATG-125 also enhanced T-cell activation, as reflected by an increased ratio of CD69+/CD3+ T cells in co-cultures of tumor cells and human PBMCs. In vivo, ATG-125 demonstrated sustained antitumor activity in HCC827 xenograft models, increased tumor infiltration of CD4+ and CD8+ T cells in PBMC-humanized models, and inhibited tumor growth in a dose-dependent manner in MC38-hB7H3 syngeneic models, accompanied by elevated intratumoral CD8+ T-cell infiltration.
Conclusion: ATG-125 demonstrated synergistic IO+ADC antitumor activity through a differentiated mechanism combining enhanced internalization for payload delivery with the potential to restore anti-tumor immunity. Its compelling preclinical profile supports further development for patients with solid tumors.
ATG-106 (CDH6 x CD3 TCE)
Title: ATG-106, a novel "2+1" format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy
Abstract Number: 1621
Session Category: Immunology
Session Title: T Cell Engagers 1
Date: April 20, 2026
Time: 09:00 AM – 12:00 PM (Pacific Time)
00:00 AM, April 21, 2026 – 03:00 AM, April 21, 2026 (Beijing Time)
Location: Poster Section 10

Introduction: CDH6 plays an important role in embryonic kidney development but has negligible expression in adult kidney tissue. Its overexpression in ovarian and renal cancers, together with limited normal tissue expression, makes CDH6 an attractive therapeutic target. However, T cell engagers in solid tumors have often been limited by insufficient efficacy and the risk of cytokine release syndrome. To address these challenges, Antengene developed ATG-106, a novel "2+1", sterically masked CDH6 x CD3 bispecific TCE designed to deliver potent antitumor activity with the potential for a reduced CRS risk profile.
Results: ATG-106 exhibited reduced binding affinity to CD3+ cells before CDH6 crosslinking, while inducing approximately 100- to 400-fold more potent cytotoxicity against CDH6-positive tumor cells compared with a "1+1" CrossMab control TCE. The molecule demonstrated potent T cell-dependent cytotoxicity in ovarian and renal cancer models and showed low immunogenicity risk in vitro. In PBMC-humanized 786-O kidney cancer xenograft models, ATG-106 induced tumor shrinkage in all treated mice, with complete remissions observed in the 0.1 mg/kg and 0.3 mg/kg groups. ATG-106 also induced tumor shrinkage and complete remission in PBMC-humanized OVCAR-3 ovarian cancer models. Notably, pro-inflammatory cytokine levels remained very low in treated animals, suggesting low CRS risk. In non-human primate studies, the surrogate molecule ATG-106-RM was well tolerated at doses up to 10 mg/kg.
Conclusion: ATG-106 demonstrated limited T cell binding in the absence of target cells, potent cytotoxicity against tumor cells, and encouraging in vivo efficacy in ovarian and kidney cancer models. Favorable safety findings with the surrogate molecule in non-human primates further support continued clinical development of ATG-106 as a CDH6-targeted TCE candidate.
ATG-112 (ALPPL2 x CD3 TCE)
Title: ATG-112, a novel ALPP/G x CD3 bispecific T cell engager, for the treatment of ALPP/G+ solid tumors
Abstract Number: 1620
Session Category: Immunology
Session Title: T Cell Engagers 1
Date: April 20, 2026
Time: 09:00 AM – 12:00 PM (Pacific Time)
00:00 AM, April 21, 2026 – 03:00 AM, April 21, 2026 (Beijing Time)
Location: Poster Section 10

Introduction: Placental alkaline phosphatase and related placental-like/germ-cell isoforms, including ALPPL2 and ALPG, are aberrantly expressed in a range of solid tumors while being largely absent from normal adult tissues except the placenta, making them highly promising tumor-selective immunotherapy targets. Antengene developed ATG-112, an ALPP/G x CD3 bispecific TCE based on the AnTenGager platform in a "2+1" format, featuring bivalent antigen binding to improve low-antigen tumor recognition and a sterically masked CD3 binding arm designed to restrict T-cell activation to the tumor microenvironment.
Results: Tissue microarray IHC analysis showed that ALPP/G expression was restricted to placental tissue among normal organs and was not detected in other normal tissues, while frequent expression was observed in endometrial and ovarian cancers, with lower prevalence in bladder, gastric and pancreatic cancers. ATG-112 demonstrated high binding affinity to both ALPP/G-positive tumor cells and recombinant proteins, with EC50 and KD values in the sub-nanomolar range. It induced robust T cell-dependent cytotoxicity against target-positive cells with picomolar EC50 values, while in vitro cytokine-release assays showed minimal cytokine secretion from human PBMCs. In vitro studies also demonstrated that the spatial masking effect of ATG-112 is reversible. Immunogenicity assessment showed low immunogenic potential, and in vivo ATG-112 delivered potent tumor suppression across multiple dose levels in humanized mouse models, with low cytokine release and controllable CRS risk at efficacious doses. The program also demonstrated strong developability characteristics.
Conclusion: ATG-112 demonstrated a compelling preclinical profile, with potent in vitro and in vivo antitumor activity and minimal cytokine release. These findings support the continued advancement of ATG-112 toward clinical development for solid tumors.

(Press release, Antengene, APR 17, 2026, View Source [SID1234664488])

On April 17, 2026 intoDNA, a global precision medicine company that provides biopharma and clinicians with decision-grade insights into DNA damage and repair biology to reduce risk, accelerate timelines, and enable truly precise patient care, reported it will present two posters at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 17-22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR poster presentation details are below:

Title: Direct measurement of NER activity using sSTRIDE-NER
Date: April 20, 2026, 9:00 a.m. – 12:00 p.m.
Track: Experimental and Molecular Therapeutics
Session: DNA Damage and Repair 2
Section: 14

Title: In situ measurement of PARP1 activity and trapping at single-strand DNA breaks
Date: April 22, 2026, 9:00 a.m. – 12:00 p.m.
Track: Experimental and Molecular Therapeutics
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 4
Section: 53

intoDNA’s poster presentation titled, Direct measurement of NER activity using sSTRIDE-NER, demonstrates that a new assay based on the STRIDE (SensiTive Recognition of Individual DNA Ends) platform, showed:

High specificity: multiple negative technical controls yielded minimal background signal.
A time-dependent increase in nuclear signal intensity, consistent with accumulation of NER-associated SSBs.
Potential to investigate mechanisms of resistance to platinum drugs, to evaluate DNA repair-targeting agents, and to support the development of functional biomarkers predictive of therapy response.
New opportunities to functionally and spatially profile NER capacity in cancer cell models and patient-derived tissue samples.
intoDNA’s poster presentation titled, In situ measurement of PARP1 activity and trapping at single-strand DNA breaks, demonstrates that sSTRIDE-PARP1, a novel in situ assay:

Directly detects PARP1 localized at single-strand DNA breaks at single-cell resolution.
Enables direct, quantitative and functional measurement of PARP1 engagement at damaged DNA within intact cells.
Distinguishes cell lines with different basal levels of PARylation and PARP1 activity.
Provides a translational platform for mechanistic characterization of PARP inhibitors, comparative profiling of PARPi trapping capacity, and development of functional biomarkers to support patient stratification, drug development, and resistance studies in DNA damage response-targeted therapies.
"Current precision medicine approaches fall short and intoDNA envisions a future where the right therapies reach the right patients, at the right time. With our panel of novel assays, biopharma and clinicians gain decision-grade insights into DNA damage and repair biology to reduce risk, accelerate timelines, and enable truly precise patient care," said Magda Kordon-Kiszala, PhD, Founder and CEO of intoDNA.

Posters are available on the intoDNA website.

(Press release, intoDNA, APR 17, 2026, View Source [SID1234664504])